OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

Another OpenAI Alum Targets Drug Discovery

Miles Wang, a researcher from OpenAI whose work focused on accelerating scientific discovery with AI, is reportedly leaving the company to launch a new startup. According to sources familiar with the matter, the new venture will concentrate on developing AI models for drug discovery and is already in discussions to raise significant capital. This move signals a continuing trend of talent from foundational AI labs spinning out to build specialized, high-value applications in critical sectors like biotechnology.

The Deal and The Strategy

The new company is reportedly in talks to raise approximately $200 million in a funding round that would value it at $2 billion. Venture capital firm Lightspeed is said to be in discussions to lead the investment, though sources caution that talks are ongoing and details could change. Wang disputed the reported funding figures but did not offer corrections. The startup's strategy may involve using AI to find new applications for existing drugs, including those that previously failed trials, a tactic that can dramatically speed up the timeline to revenue by leveraging medicines with established safety profiles.

• Founder: Miles Wang (ex-OpenAI)
• Focus: AI models for drug discovery, potentially drug repurposing
• Reported Funding Target: ~$200 million
• Reported Valuation: $2 billion
• Potential Lead Investor: Lightspeed

A Crowded, Well-Funded Field

Wang's venture enters a competitive and capital-intensive market that has attracted substantial investor interest. It joins other well-funded players aiming to apply AI to life sciences. For instance, Chai Discovery, a two-year-old startup with a similar mission, recently announced a $400 million fundraise at a $3.8 billion valuation. Meanwhile, Google DeepMind spinout Isomorphic Labs secured a $2.1 billion Series B in May, underscoring the enormous financial backing and strategic importance placed on AI's potential to reshape pharmaceutical research and development.

The migration of top-tier talent from foundational model labs like OpenAI to vertical-specific applications signals a market shift where investors are increasingly betting on specialized execution in high-margin sectors like biotech over generalized research.